Jefferies maintains Hollis-Eden at hold

Jefferies & Co., Inc. analyst Adam Walsh maintained Hollis-Eden Pharmaceuticals Inc. at its hold rating despite positive exposure for the company on the TV show, 60 Minutes. Jefferies did not adjust its Neumune estimates but raised its price target to $7 from $5 on the possibility of a larger-than-expected Neumune contract from the Department of Defense. The low number of acute radiation syndrome treatment courses requested in the RFP is the only official indication of the end market size for Neumune. Shares of the San Diego pharmaceutical company were up 57 cents, or 9.09%, at $6.84 on volume of 6,650,566 shares versus the three-month running average of 182,295 shares. (Nasdaq: HEPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.